Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors
08 February 2022 - 1:00AM
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical
company developing a broad portfolio of product candidates
engineered to cross the blood-brain barrier (BBB) for
neurodegenerative diseases, today announced that Erik Harris has
joined the Board of Directors. Mr. Harris’ extensive biotech
leadership and pharmaceutical experience includes 20 years in all
aspects of commercial operations and achieving successful product
launches in multiple therapeutic areas, including neurological and
rare diseases.
“I’m excited to welcome Erik to our Board of Directors,” said
Ryan Watts, Ph.D., Denali’s Chief Executive Officer. “Erik’s
experience and perspective will be valuable as we now transition to
a late-stage development company with a diverse portfolio of
therapeutic candidates and continue to build out our commercial
capabilities with the goal to ultimately bring medicines to
patients with neurodegenerative and lysosomal diseases.”
“Denali is making significant progress toward a global
organization serving patients with neurodegenerative diseases,”
said Mr. Harris. “I am very excited to join Denali’s Board of
Directors. I look forward to contributing to Denali by applying my
insights in bringing high-impact, novel medicines to patients and
their families.”
Erik Harris currently serves as the Chief Commercial Officer and
Executive Vice President of Ultragenyx Pharmaceutical Inc., a
biopharmaceutical company focused on the development of a diverse
portfolio of therapies for patients with rare and ultra-rare
genetic diseases. Mr. Harris joined Ultragenyx in 2017 as Senior
Vice President and Head of North American Commercial Operations.
Earlier in his career he held positions in the commercial
organizations at Crescendo Bioscience, Intermune, Elan
Pharmaceuticals, Inc., Genentech, Inc., and Bristol Myers Squibb
Company. In addition to the launch of Ultragenyx’s Crysvita®,
Mepsevii®, and Dojolvi®, Mr. Harris has been involved in the
launches of Tarceva®, Tysabri® and Vectra-DA®. To begin his
professional career, Mr. Harris served as a Lieutenant Commander in
Naval Aviation and Congressional Fellow for the United States Navy.
Mr. Harris received his Masters of Business Administration at the
Wharton School of Business, and Bachelor of Science at the United
States Naval Academy.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a
broad portfolio of product candidates engineered to cross the
blood-brain barrier (BBB) for neurodegenerative diseases. Denali
pursues new treatments by rigorously assessing genetically
validated targets, engineering delivery across the BBB and guiding
development through biomarkers that demonstrate target and pathway
engagement. Denali is based in South San Francisco. For additional
information, please visit www.denalitherapeutics.com
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements expressed or implied
in this press release include, but are not limited to, statements
regarding Denali's progress, business plans, business strategy,
product candidates, planned preclinical studies and clinical trials
and expectations; and statements made by Denali’s Chief Executive
Officer. Actual results are subject to risks and uncertainties and
may differ materially from those indicated by these forward-looking
statements as a result of these risks and uncertainties, including
but not limited to, risks related to: any and all risks to Denali’s
business and operations caused directly or indirectly by the
evolving COVID-19 pandemic; risk of the occurrence of any event,
change or other circumstance that could give rise to the
termination of Denali’s collaboration agreements; Denali’s early
stages of clinical drug development; Denali’s and its partners’
ability to complete the development and, if approved,
commercialization of its product candidates; Denali’s reliance on
third parties for the manufacture and supply of its product
candidates for clinical trials; Denali’s and it's partners' ability
to conduct or complete clinical trials on expected timelines; the
uncertainty that product candidates will receive regulatory
approval necessary to be commercialized; Denali’s ability to
continue to create a pipeline of product candidates or develop
commercially successful products; Denali’s ability to obtain,
maintain, or protect intellectual property rights related to its
product candidates; implementation of Denali’s strategic plans for
its business, product candidates and blood-brain barrier platform
technology; and other risks, including those described in Denali’s
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) on November 4, 2021, Denali’s Annual
Report on Form 10-K filed with the SEC on February 26, 2021, and
Denali’s future reports to be filed with the SEC. The
forward-looking statements in this press release are based on
information available to Denali as of the date hereof. Denali
disclaims any obligation to update any forward-looking statements,
except as required by law.
Investor Relations Contact:
Laura Hansen, Ph.D.Vice President, Investor Relations(650)
452-2747hansen@dnli.com
Media Contacts:
Lizzie Hyland(646) 495-2706Lizzie.hyland@fgh.com
or
Morgan Warners(202) 295-0124Morgan.warners@fgh.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024